Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

mpany implemented a one-for-ten reverse split of all outstanding shares of its common stock and a corresponding decrease in the number of shares of authorized common stock. Share and per share amounts contained herein are provided on a post-split basis.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to c
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... 19, 2014 The report "Chocolate, Cocoa ... Trade, Prices, Geography Trend and Forecast (2011 - 2016)," ... and geography and studies the major market drivers, restraints, ... Europe, and Asia. , The global chocolate market is ... billion in 2016 at an estimated CAGR of 2.7% ...
(Date:10/19/2014)... According to market research report “Outdoor Wi-Fi Market ... Global Advancements, Forecasts and Analysis (2013 - 2018)", ... with analysis and forecasting of the global revenues. ... and the restrains for this market with the ... Browse 65 market data tables and 69 figures ...
(Date:10/18/2014)... (PRWEB) October 18, 2014 The ... - Trends and Forecasts to 2019", analyzes the ... in order to understand the industry details such ... opportunities across various geographic regions. , Browse 81 ... 202 Slides and in-depth TOC on “1,6-Hexanediol Market ...
(Date:10/18/2014)... The Asia-Pacific Liquid Crystal on Silicon (LCoS) display ... Asia-Pacific with analysis and forecast of revenue. This market ... expected to reach $380.0 million by 2018, at a ... through the TOC of the Asia-Pacific LCoS display market ... provided. This also provides a glimpse of the segmentation ...
Breaking Biology Technology:Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3
... ... HPCwire,s Readers, Choice Award for Best Application of Green Computing. The award was ... ongoing in Portland, Ore. , ... Portland, OR (Vocus) Nov. 17, 2009 --- The U.S. Department of Energy,s ...
... Pharma guarantees to purchase 50,000 KINLYTIC vials over next ... Biosystems Inc. (MBX:TSX), a biotech company focused on virology ... agreement with Riso Pharma that guarantees purchases of not ... years. KINLYTIC (Urokinase) is Microbix, thrombolytic agent for treating ...
... , ROCKVILLE, Md., Nov. 17 Neuralstem, Inc. (NYSE Amex: ... the third quarter ended September 30, 2009. , (Logo: ... of 2009, the Company reported a net loss of $5,096,983, or ... $0.10 per share, for the comparable 2008 period. The increase was ...
Cached Biology Technology:Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 2Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 3Argonne Recognized for "Green Computing" in 2009 HPCwire Readers' and Editors' Choice Awards 4Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region 2Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 2Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 3Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 4Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 5Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 6Neuralstem, Inc. Reports Third Quarter Financial Results and Provides Business Update 7
(Date:10/14/2014)... ATHENS, Ohio (Oct. 14, 2014)—It,s been millions of years ... but a team led by Ohio University scientists is ... to model airflow through dinosaur snouts. The research has ... not only breathe but to enhance the sense of ... pretty ,nosy, animals," said Ohio University doctoral student Jason ...
(Date:10/14/2014)... 14, 2014 – High doses of fish oil supplements, rich ... common type of irregular heartbeat in which the heart can ... of the AFFORD trial led by the Montreal Heart Institute ... of Cardiology on October 7th. , For the trial, ... were randomly assigned to 4 grams of fish oil a ...
(Date:10/14/2014)... between 10 and 20 years to develop, providing ... intervention if detected early, which may be possible ... clinical researchers. , Dr Jeremy Humphris and ... Medical Research, analysed medical histories and tumour samples ... patients, operated on between 1994 and 20122. Roughly ...
Breaking Biology News(10 mins):Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Early detection window when pancreatic cancer is in the family 2
... a long-distance race may do serious harm rather than ... much, according to a cardiologist at UT Southwestern Medical ... too much water during a race could put themselves ... a loss in the body's sodium content that can ...
... announced today the launch of the new GeneChip(R) ... with PreAnalytiX -- a joint venture between QIAGEN ... BD (Becton, Dickinson and Company). The new kits ... use with Affymetrix GeneChip technology and improve gene ...
... Earth history some 251 million years ago was preceded by ... by a delayed recovery that lasted for millions of years. ... a sharp decline in atmospheric oxygen levels was likely a ... very slow recovery. , Earth's land at the time was ...
Cached Biology News:Too much water may be as dangerous as too little during long-distance athletic events 2Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 2Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX 3Scientists reveal the shape of a protein that helps retroviruses break into cells 2Scientists reveal the shape of a protein that helps retroviruses break into cells 3
75 x 25 mm; sterile, recommended for immunohistochemistry of cell lines growing in suspension, Poly-D-Lysine coated, glass slides with polystyrene vessel, lid and safety removal tool...
IMAGEQUANT 400 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
IMAGEQUANT 400 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
ImageQuant 100 UV, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: